Soligenix Shares Resume Trade
Save time and jump to the most important pieces.
4 - SOLIGENIX, INC. (0000812796) (Issuer)
4 - SOLIGENIX, INC. (0000812796) (Issuer)
4 - SOLIGENIX, INC. (0000812796) (Issuer)
Phase 3 clinical study of HyBryte™ in CTCL initiating in 2024 PRINCETON, N.J., Nov. 19, 2024 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the formation of a European Medical Advisory Board (MAB) to provide additional medical/clinical strategic guidance to the Company as it advances its confirmatory Phase 3 multicenter, double-blind, placebo-controlled study evaluating the safety and efficacy of HyBryte™ (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL) patients with early-st
PRINCETON, NJ / ACCESSWIRE / November 15, 2024 / Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it will be presenting at the upcoming Q4 Investor Summit and will be available for 1-on-1 meetings throughout the day.Event: Q4 Investor SummitPresentation Time: 12:00pm - 12:30pm ETLocation: https://www.webcaster4.com/Webcast/Page/3075/51675The theme is 40 micro-cap companies with a catalyst and/or strong performance in the current market.Take a deep dive with the best Investors in MicroCapLive Q & AComplimentary to
Study DUS-AUBD-01 opens patient enrollment PRINCETON, N.J., Nov. 14, 2024 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has opened patient enrollment for its Phase 2 study (protocol number DUS-AUBD-01) evaluating SGX945 (dusquetide) in the treatment of Behçet's Disease. "We are pleased to have received FDA clearance and Turkish Medicines and Medical Devices Agency (Turkey's Min
ORLANDO, FL / ACCESSWIRE / September 20, 2024 / RedChip Companies will air interviews with Nova Minerals Limited (NASDAQ:NVA) and Soligenix Inc. (NASDAQ:SNGX) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, September 21, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Nova Minerals: https://www.redchip.com/assets/access/nva_accessSoligenix: https://www.redchip.com/assets/access/sngx_accessChristopher Gerteisen, CEO of Nova Minerals, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update. Nova Minerals p
ORLANDO, FL / ACCESSWIRE / August 16, 2024 / RedChip Companies will air interviews with Soligenix Inc. (NASDAQ:SNGX) and American Resources Corp. (NASDAQ:AREC) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, August 17, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Soligenix: https://www.redchip.com/assets/access/sngx_accessAmerican Resources: https://www.redchip.com/assets/access/arec_accessIn an exclusive interview, Christopher J. Schaber, PhD, President and CEO of Soligenix, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / June 7, 2024 / RedChip Companies will air interviews with Soligenix, Inc. (NASDAQ:SNGX) and Sharps Technology Inc. (NASDAQ:STSS) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, June 8, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Soligenix: https://www.redchip.com/assets/access/sngx_accessSharps Technology: https://www.redchip.com/assets/access/stss_accessIn an exclusive interview, Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix, appears on the RedChip Small Stocks Big Money™ show on B
424B3 - SOLIGENIX, INC. (0000812796) (Filer)
424B3 - SOLIGENIX, INC. (0000812796) (Filer)
424B3 - SOLIGENIX, INC. (0000812796) (Filer)
PRINCETON, N.J., Sept. 22, 2023 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its 2023 Annual Meeting of Stockholders (the "Annual Meeting") scheduled for and convened on September 21, 2023 has been adjourned for the purpose of soliciting additional votes with respect to the proposals described in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission (the "SEC") on August 7, 2023 (the "Proxy Statement"). As a result of the additional ti
Strengthens regulatory and orphan drug development expertise PRINCETON, N.J., May 3, 2023 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the appointment of Timothy R. Coté, M.D., M.P.H. to its Board of Directors. Dr. Coté is a leading national regulatory expert in orphan drug development. With 23 years of Federal service at the U.S. Food and Drug Administration (FDA), National Institu
- Meeting adjourned to October 19, 2022, at 9:00 a.m., Eastern Time - Soligenix encourages all stockholders of record at the close of business on July 25, 2022 who have not yet voted, to vote by 11:59 p.m., Eastern Time on October 18, 2022 PRINCETON, N.J., Sept. 23, 2022 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its 2022 Annual Meeting of Stockholders (the "Annual Meeting") scheduled for and convened on September 22, 2022 has been partially adjourned for the purpose of soliciting add
Shares of SeaStar Medical Holding Corporation (NASDAQ:ICU) fell sharply during Wednesday's session after the company entered into a $10 million registered direct offering of 947,868 shares at $10.55 per share. SeaStar Medical shares dipped 34% to $8.55 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) shares jumped 139% to $2.78 after the company announced results for a Swine Model pilot study for Probudur. Kazia Therapeutics Limited (NASDAQ:KZIA) gained 129% to $0.4325 after the company announced results from GBM-AGILE, a phase II/III study that included an evaluation of paxalisib versus standard of
Shares of VivoPower International PLC (NASDAQ:VVPR) rose sharply in today's pre-market trading after the company announced it secured an extension for a $34 million loan financing facility agreement. VivoPower International shares jumped 31.4% to $3.35 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Ampco-Pittsburgh Corporation (NYSE:AP) rose 72.6% to $1.32 in pre-market trading. Seelos Therapeutics, Inc. (NASDAQ:SEEL) shares rose 40.4% to $0.9516 in pre-market trading after gaining 36% on Tuesday. NaaS Technology Inc. (NASDAQ:NAAS) gained 40% to $4.55 in pre-market trading after surging 68% on Tuesday. Soligenix, Inc. (NASDAQ:SNG
U.S. stocks traded mixed toward the end of trading, with the S&P 500 gaining around 0.1% on Tuesday. The Dow traded down 0.05% to 39,323.7 while the NASDAQ rose 0.10% to 18,422.24. The S&P 500 also rose, gaining, 0.12% to 5,579.76. Check This Out: Nvidia To Rally Over 40%? Here Are 10 Top Analyst Forecasts For Tuesday Leading and Lagging SectorsFinancials shares jumped by 1.1% on Tuesday. In trading on Tuesday, materials shares fell by 0.6%. Top Headline Helen of Troy Limited (NASDAQ:HELE) reported soft first-quarter earnings and lowered its FY25 guidance. Equities Trading UP Soligenix, Inc. (NASDAQ:SNGX) shares shot up 379% to $9.59 after the